Robert Kalis

Robert Kalis

Auto-generated profile, based on publicly available information

Robert Kalis

Research Institute of Molecular Pathology (IMP), Vienna Biocenter (VBC), Campus-Vienna-Biocenter 1, 1030 Vienna, Austria

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 October 2021 in Nature
Verified
Journal Article
Closed access
PDF file
MAMelanie de Almeida
Melanie de Almeida
MHMatthias Hinterndorfer
Matthias Hinterndorfer
HBHanna Brunner
Hanna Brunner
IGIrina Grishkovskaya
Irina Grishkovskaya
KSKashish Singh
Kashish Singh
JZJohannes Zuber
Johannes Zuber

7 October 2022 in Science
Verified
Journal Article
Closed access
CPCatarina Pechincha
Catarina Pechincha
SGSven Groessl
Sven Groessl
RKRobert Kalis
Robert Kalis
MAMelanie de Almeida
Melanie de Almeida
AZAndrea Zanotti
Andrea Zanotti
WPWilhelm Palm
Wilhelm Palm
Mammalian cells can generate amino acids through macropinocytosis and lysosomal breakdown of extracellular proteins, which is exploited by cancer cells to grow in nutrient-poor tumors. Through genetic screens in defined nutrient conditions, we characterized LYSET, a transmembrane protein (TMEM251) selectively required when cells consume extracellular proteins. LYSET was found to associate in the Golgi with GlcNAc-1-phosphotransferase, which targets catabolic enzymes to lysosomes through mannose-6-phosphate modification. Without LYSET, GlcNAc-1-phosphotransferase was unstable because of a hydrophilic transmembrane domain. Consequently, LYSET-deficient cells were depleted of lysosomal enzymes and impaired in turnover of macropinocytic and autophagic cargoes. Thus, LYSET represents a core component of the lysosomal enzyme trafficking pathway, underlies the pathomechanism for hereditary lysosomal storage disorders, and may represent a target to suppress metabolic adaptations in cancer.

9 October 2025 in Science
Verified
Journal Article
Closed access
SGSven Groessl
Sven Groessl
RKRobert Kalis
Robert Kalis
MSMarteinn T. Snaebjornsson
Marteinn T. Snaebjornsson
LWLeon Wambach
Leon Wambach
JHJakob Haider
Jakob Haider
JZJohannes Zuber
Johannes Zuber
Malignant tumors are characterized by diverse metabolic stresses, including nutrient shortages, hypoxia, and buildup of metabolic by-products. To understand how cancer cells adapt to such challenges, we conducted sequential CRISPR screens to identify genes that affect cellular fitness under specific metabolic stress conditions in cell culture and to then probe their relevance in pancreatic tumors. Comparative analyses of hundreds of fitness genes revealed that cancer metabolism in vivo was shaped by bioenergetic adaptations to tumor acidosis. Mechanistically, acidosis suppressed cytoplasmic activity of extracellular signal–regulated kinase (ERK), thereby preventing oncogene-induced mitochondrial fragmentation and promoting fused mitochondria. The resulting boost in mitochondrial respiration supported cancer cell adaptations to various metabolic stresses. Thus, acidosis is an environmental factor that alters energy metabolism to promote stress resilience in cancer.

24 March 2023 in eLife
Verified
Journal Article
Open access
SSSara Scinicariello
Sara Scinicariello
ASAdrian Soderholm
Adrian Soderholm
MSMarkus Schäfer
Markus Schäfer
ASAlexandra Shulkina
Alexandra Shulkina
ISIrene Schwartz
Irene Schwartz
GVGijs Versteeg
Gijs Versteeg
Tristetraprolin (TTP) is a critical negative immune regulator. It binds AU-rich elements in the untranslated-regions of many mRNAs encoding pro-inflammatory mediators, thereby accelerating their decay. A key but poorly understood mechanism of TTP regulation is its timely proteolytic removal: TTP is degraded by the proteasome through yet unidentified phosphorylation-controlled drivers. In this study, we set out to identify factors controlling TTP stability. Cellular assays showed that TTP is strongly lysine-ubiquitinated, which is required for its turnover. A genetic screen identified the ubiquitin E3 ligase HUWE1 as a strong regulator of TTP proteasomal degradation, which we found to control TTP stability indirectly by regulating its phosphorylation. Pharmacological assessment of multiple kinases revealed that HUWE1-regulated TTP phosphorylation and stability was independent of the previously characterized effects of MAPK-mediated S52/S178 phosphorylation. HUWE1 function was dependent on phosphatase and E3 ligase binding sites identified in the TTP C-terminus. Our findings indicate that while phosphorylation of S52/S178 is critical for TTP stabilization at earlier times after pro-inflammatory stimulation, phosphorylation of the TTP C-terminus controls its stability at later stages.

6 May 2025 in Nature Communications
Verified
Journal Article
Open access
PDF file
JHJulia Hermann
Julia Hermann
TBToman Borteçen
Toman Borteçen
RKRobert Kalis
Robert Kalis
AKAlexander Kowar
Alexander Kowar
CPCatarina Pechincha
Catarina Pechincha
WPWilhelm Palm
Wilhelm Palm
Synthesizing the cellular proteome is a demanding process that is regulated by numerous signaling pathways and RNA modifications. How precisely these mechanisms control the protein synthesis machinery to generate specific proteome subsets remains unclear. Here, through genome-wide CRISPR screens we identify genes that enable mammalian cells to adapt to inactivation of the kinase mechanistic target of rapamycin complex 1 (mTORC1), the central driver of protein synthesis. When mTORC1 is inactive, enzymes that modify tRNAs at wobble uridines (U34-enzymes), Elongator and Ctu1/2, become critically essential for cell growth in vitro and in tumors. By integrating quantitative nascent proteomics, steady-state proteomics and ribosome profiling, we demonstrate that the loss of U34-enzymes particularly impairs the synthesis of ribosomal proteins. However, when mTORC1 is active, this biosynthetic defect only mildly affects steady-state protein abundance. By contrast, simultaneous suppression of mTORC1 and U34-enzymes depletes cells of ribosomal proteins, globally inhibiting translation. Thus, mTORC1 cooperates with tRNA U34-enzymes to sustain the protein synthesis machinery and support the high translational requirements of cell growth.

8 April 2025 in bioRxiv
Verified
Preprint
Open access
SASascha J. Amann
Sascha J. Amann
RKRobert Kalis
Robert Kalis
MFMaximilian Fottner
Maximilian Fottner
HKHannah Knaudt
Hannah Knaudt
IGIrina Grishkovskaya
Irina Grishkovskaya
DHDavid Haselbach
David Haselbach
Proteasomal degradation is a fundamental process for all eukaryotic life. A protein destined for degradation is first tagged with a polyubiquitin chain, which is selected by the proteasome. Different ubiquitin chain topologies serve as distinct signals, with K48-linked chains acting as the canonical degradation signal and K11/K48-branched chains providing even more potent targeting, particularly during cell cycle regulation. However, the structural basis for how the proteasome distinguishes between these different chain architectures has remained unclear. Here, we present high-resolution cryo-EM structures of the human 26S proteasome bound to both a K48-linked tetraubiquitin chain and a K11/K48-branched chain. Our structures reveal distinct binding modes for these two types of chain linkage. K48 chains wrap around the Ubiquitin interaction motif of the receptor RPN10 in an unexpected spiral conformation, while K11 branches engage the proteasome through previously uncharacterised interfaces in a cleft formed between RPN2 and RPN10. Through structure-guided mutagenesis and cellular studies, we demonstrate that these binding modes are essential for efficient substrate degradation and cell cycle progression. These findings establish how the proteasome achieves selective substrate recognition through chain topology-specific interactions.